Preventing and ameliorating chronic conditions has long been a priority in the United States; however, the increasing recognition that people often have multiple chronic conditions (MCC) has added a layer of complexity with which to contend. The objective of this study was to present the prevalence of MCC and the most common MCC dyads/triads by selected demographic characteristics. We used respondent-reported data from the 2010 National Health Interview Survey (NHIS) to study the US adult civilian noninstitutionalized population aged 18 years or older (n = 27,157). We categorized adults as having 0 to 1, 2 to 3, or 4 or more of the following chronic conditions: hypertension, coronary heart disease, stroke, diabetes, cancer, arthritis, hepatitis, weak or failing kidneys, chronic obstructive pulmonary disease, or current asthma. We then generated descriptive estimates and tested for significant differences. Twenty-six percent of adults have MCC; the prevalence of MCC has increased from 21.8% in 2001 to 26.0% in 2010. The prevalence of MCC significantly increased with age, was significantly higher among women than men and among non-Hispanic white and non-Hispanic black adults than Hispanic adults. The most common dyad identified was arthritis and hypertension, and the combination of arthritis, hypertension, and diabetes was the most common triad. The findings of this study contribute information to the field of MCC research. The NHIS can be used to identify population subgroups most likely to have MCC and potentially lead to clinical guidelines for people with more common MCC combinations.
Chronic conditions are an increasing concern in the United States, where they affect nearly half of the adult population and their prevalence has increased in recent years (
Although numerous data sources are available to help meet these data-driven objectives, the National Health Interview Survey (NHIS) can be used to generate estimates of MCC that are representative of the noninstitutionalized, civilian adult population of the United States. The NHIS contains extensive sociodemographic and health data that can be studied with MCC. Furthermore, because it is conducted continuously, it can be used to monitor trends in MCC over time.
The main objective of this study was to use nationally representative data from the 2010 NHIS to examine the prevalence of MCC by select sociodemographic groups, and the prevalence of MCC dyads and triads among US adults. A secondary objective was to use earlier data from the NHIS to examine trends in MCC during 2001–2010.
The NHIS is a multipurpose health survey that represents the US civilian, noninstitutionalized population (
| Variable | % (95% Confidence Interval) |
|---|---|
|
| |
| Men | 48.3 (47.57–49.09) |
| Women | 51.7 (50.91–52.43) |
|
| |
| 18–44 | 48.2 (47.32–49.08) |
| 45–64 | 34.9 (34.19–35.70) |
| ≥65 | 16.9 (16.26–17.47) |
|
| |
| Non-Hispanic white | 68.0 (67.13–68.91) |
| Non-Hispanic black/African American | 11.6 (11.03–12.26) |
| Hispanic | 14.0 (13.38–14.61) |
| Non-Hispanic Asian/Pacific Islander | 4.7 (4.38–5.05) |
| Non-Hispanic American Indian/Alaska Native | 0.5 (0.39–0.67) |
| Non-Hispanic other race | 1.1 (0.99–1.33) |
|
| |
| Public | 16.0 (15.38–16.59) |
| Private | 62.9 (62.03–63.79) |
| Other | 3.1 (2.87–3.44) |
| Uninsured | 18.0 (17.34–18.60) |
The HHS Interagency Workgroup on MCC and Office of the Assistant Secretary for Health have generated a standardized approach to defining chronic conditions in the United States (
The NHIS questions on chronic conditions included in this article remained consistent for the 2001 through 2010 NHIS surveys, with 1 exception: in 2001 the NHIS asked sample adults if they had arthritis, with no reference to rheumatoid arthritis, gout, lupus, or fibromyalgia. From 2002 and onward, the question on arthritis included all 5 conditions (ie, arthritis, rheumatoid arthritis, gout, lupus, and fibromyalgia). The 10 conditions included in this HHS standardized approach (
To account for survey weights that allow for generalization to the US adult civilian noninstitutionalized population and the additional covariance resulting from the complex cluster sampling design used by the NHIS, we used SUDAAN version 10.0.1 (RTI International, Research Triangle Park, North Carolina) to generate all descriptive estimates and their corresponding confidence intervals. Two-tailed significance tests were used to test for significant differences in prevalence among population subgroups in 2010, and all differences noted in this article are significant (
In 2010, 49.1% of civilian, noninstitutionalized US adults had no chronic conditions, and 24.8% had only 1 chronic condition. One-quarter of US adults had MCC (
| Sex, Age, and Race/Ethnicity | No. of Chronic Conditions | ||
|---|---|---|---|
| 0–1, % (95% CI) | 2–3, % (95% CI) | ≥4, % (95% CI) | |
|
| 74.0 (73.28–74.63) | 21.1 (20.50–21.74) | 4.9 (4.62–5.24) |
|
| |||
|
| |||
| Total | 93.3 (92.49–94.07) | 6.3 (5.57–7.11) | 0.4 (0.23–0.64) |
| Non-Hispanic white | 93.6 (92.55–94.46) | 6.1 (5.23–7.11) | 0.3 (0.15–0.73) |
| Non-Hispanic black/African American | 91.2 (88.56–93.23) | 8.0 (6.06–10.46) | 0.8 (0.33–2.11) |
| Hispanic | 93.7 (91.76–95.21) | 6.0 (4.53–7.93) |
—
|
| Non-Hispanic Asian/Pacific Islander | 96.5 (93.51–98.13) | 3.4 (1.76–6.36) |
—
|
| Non-Hispanic American Indian/Alaska Native | 86.7 (55.37–97.16) |
—
|
—
|
| Non-Hispanic other race | 86.1 (73.41–93.26) | 12.8 (5.89–25.64) |
—
|
|
| |||
| Total | 67.2 (65.44–68.91) | 28.1 (26.50–29.79) | 4.7 (3.99–5.49) |
| Non-Hispanic white | 66.3 (64.12–68.44) | 28.4 (26.49–30.48) | 5.2 (4.36–6.29) |
| Non-Hispanic black/African American | 61.6 (56.57–66.30) | 33.7 (29.13–38.69) | 4.7 (3.24–6.79) |
| Hispanic | 76.6 (72.26–80.50) | 21.4 (17.61–25.65) | 2.0 (1.19–3.38) |
| Non-Hispanic Asian/Pacific Islander | 78.6 (71.56–84.27) | 19.5 (14.08–26.45) |
—
|
| Non-Hispanic American Indian/Alaska Native | 28.5 (10.28–58.20) | 66.8 (37.31–87.19) |
—
|
| Non-Hispanic other race | 62.6 (44.99–77.41) | 32.9 (18.26–51.92) |
—
|
|
| |||
| Total | 37.5 (35.17–39.85) | 45.4 (42.92–47.88) | 17.1 (15.31–19.13) |
| Non-Hispanic white | 36.9 (34.24–39.62) | 45.7 (42.91–48.60) | 17.4 (15.29–19.68) |
| Non-Hispanic black/African American | 32.3 (26.40–38.83) | 48.6 (42.25–55.03) | 19.1 (14.49–24.70) |
| Hispanic | 47.5 (40.39–54.76) | 40.1 (33.30–47.22) | 12.4 (8.53–17.71) |
| Non-Hispanic Asian/Pacific Islander | 39.4 (29.26–50.59) | 45.1 (34.75–55.85) | 15.5 (8.47–26.69) |
| Non-Hispanic American Indian/Alaska Native |
—
|
—
| 100.0 (n/a) |
| Non-Hispanic other race | 50.8 (29.75–71.58) | 30.4 (13.70–54.70) |
—
|
|
| |||
|
| |||
| Total | 91.1 (90.26–91.95) | 8.0 (7.26–8.91) | 0.8 (0.59–1.11) |
| Non-Hispanic white | 91.0 (89.81–92.12) | 8.2 (7.20–9.42) | 0.7 (0.45–1.17) |
| Non-Hispanic black/African American | 88.3 (86.00–90.20) | 10.3 (8.48–12.45) | 1.4 (0.87–2.38) |
| Hispanic | 92.9 (91.19–94.23) | 6.8 (5.42–8.42) | 0.4 (0.19–0.73) |
| Non-Hispanic Asian/Pacific Islander | 97.1 (94.40–98.51) | 2.8 (1.38–5.46) |
—
|
| Non-Hispanic American Indian/Alaska Native | 84.2 (63.87–94.17) |
—
|
—
|
| Non-Hispanic other race | 83.2 (72.29–90.39) | 12.9 (6.70–23.50) |
—
|
|
| |||
| Total | 65.2 (63.64–66.73) | 28.1 (26.65–29.56) | 6.7 (5.97–7.54) |
| Non-Hispanic white | 66.8 (64.87–68.62) | 27.3 (25.55–29.06) | 6.0 (5.08–6.98) |
| Non-Hispanic black/African American | 52.0 (47.92–56.14) | 36.8 (33.05–40.62) | 11.2 (8.96–13.91) |
| Hispanic | 65.9 (61.82–69.75) | 26.7 (23.21–30.52) | 7.4 (5.63–9.67) |
| Non-Hispanic Asian/Pacific Islander | 79.9 (73.37–85.16) | 18.6 (13.52–25.10) | 1.5 (0.67–3.20) |
| Non-Hispanic American Indian/Alaska Native | 52.6 (31.78–75.52) | 42.8 (23.61–64.50) |
—
|
| Non-Hispanic other race | 48.5 (34.78–62.45) | 27.7 (17.68–40.53) | 23.8 (14.12–37.32) |
|
| |||
| Total | 38.2 (36.22–40.18) | 47.4 (45.44–49.30) | 14.5 (13.09–15.94) |
| Non-Hispanic white | 38.2 (35.83–40.53) | 47.4 (45.12–49.67) | 14.5 (12.88–16.19) |
| Non-Hispanic black/African American | 33.6 (28.98–38.45) | 52.3 (47.29–57.18) | 14.2 (11.13–17.93) |
| Hispanic | 40.6 (34.82–46.75) | 43.7 (38.03–49.50) | 15.7 (11.48–21.04) |
| Non-Hispanic Asian/Pacific Islander | 49.6 (40.80–58.43) | 40.9 (32.76–49.54) | 9.5 (5.33–16.42) |
| Non-Hispanic American Indian/Alaska Native |
—
| 56.3 (25.52–82.89) |
—
|
| Non-Hispanic other race |
—
| 47.7 (27.04–69.20) | 32.7 (12.96–61.29) |
Abbreviations: CI, confidence interval; n/a, not applicable.
Adults identifying as multiple races were included in the “other race” category.
Relative standard error (RSE) >30% and ≤50% and should be used with caution as they do not meet National Center for Health Statistics standards of reliability and precision.
RSE >50% are not shown.
Estimates with a quantity of zero.
Significant differences in the prevalence of MCC were found when the analysis was further stratified by race/ethnicity (
Differences in the prevalence of MCC were also found among specific racial/ethnic categories for certain sex/age groups (
For all 3 age groups, non-Hispanic black women had a higher prevalence of 2 to 3 MCC compared with Hispanic women (
| Sex, Age, and Health Insurance, Race/Ethnicity | No. of Chronic Conditions | ||
|---|---|---|---|
| 0–1, % (95% CI) | 2–3, % (95% CI) | ≥4, % (95% CI) | |
|
| |||
|
| |||
| Public, total | 83.9 (79.44–87.53) | 14.2 (10.78–18.47) | 1.9 (0.89–4.06) |
| Public, non-Hispanic white | 81.9 (74.43–87.49) | 16.2 (10.92–23.25) |
—
|
| Public, non-Hispanic black/African American | 81.2 (71.56–88.17) | 17.6 (10.78–27.34) |
—
|
| Public, Hispanic | 89.7 (81.13–94.62) | 8.1 (3.90–15.95) |
—
|
| Private, total | 94.0 (92.88–94.91) | 5.9 (4.96–6.97) |
—
|
| Private, non-Hispanic white | 94.6 (93.31–95.58) | 5.4 (4.40–6.67) |
—
|
| Private, non-Hispanic black/African American | 93.5 (90.04–95.87) | 5.4 (3.40–8.32) |
—
|
| Private, Hispanic | 91.6 (87.68–94.40) | 8.2 (5.44–12.14) |
—
|
| Other, total | 86.3 (77.85–91.83) | 11.2 (6.25–19.16) |
—
|
| Other, non-Hispanic white | 83.1 (69.69–91.33) | 12.7 (5.88–25.45) |
—
|
| Other, non-Hispanic black/African American | 86.0 (60.53–96.12) |
—
|
—
|
| Other, Hispanic | 92.0 (79.29–97.16) |
—
|
—
|
| Uninsured, total | 94.7 (93.29–95.86) | 4.9 (3.85–6.31) |
—
|
| Uninsured, non-Hispanic white | 94.1 (91.62–95.91) | 5.4 (3.70–7.69) |
—
|
| Uninsured, non-Hispanic black/African American | 93.2 (89.11–95.87) | 6.3 (3.75–10.41) |
—
|
| Uninsured, Hispanic | 95.9 (93.68–97.33) | 4.0 (2.58–6.20) |
—
|
|
| |||
| Public, total | 38.4 (32.85–44.23) | 44.7 (39.10–50.39) | 16.9 (13.27–21.38) |
| Public, non-Hispanic white | 33.9 (26.36–42.35) | 44.7 (37.04–52.54) | 21.4 (15.97–28.17) |
| Public, non-Hispanic black/African American | 41.3 (31.48–51.86) | 47.8 (37.31–58.52) | 10.9 (6.09–18.70) |
| Public, Hispanic | 51.2 (37.37–64.92) | 39.5 (26.52–54.22) | 9.2 (4.54–17.84) |
| Private, total | 69.3 (67.14–71.35) | 27.3 (25.37–29.40) | 3.4 (2.60–4.35) |
| Private, non-Hispanic white | 68.9 (66.43–71.34) | 27.3 (25.07–29.73) | 3.7 (2.79–4.95) |
| Private, non-Hispanic black/African American | 62.1 (55.54–68.30) | 34.5 (28.59–41.04) | 3.3 (1.67–6.47) |
| Private, Hispanic | 74.9 (68.02–80.68) | 23.9 (18.24–30.74) |
—
|
| Other, total | 56.2 (48.84–63.28) | 33.7 (27.13–40.96) | 10.1 (6.92–14.54) |
| Other, non-Hispanic white | 59.2 (49.57–68.17) | 29.5 (21.52–38.94) | 11.3 (7.12–17.53) |
| Other, non-Hispanic black/African American | 42.3 (29.29–56.40) | 48.7 (34.82–62.72) | 9.1 (4.35–17.98) |
| Other, Hispanic | 59.3 (33.80–80.65) | 38.5 (17.76–64.41) |
—
|
| Uninsured, total | 76.8 (72.88–80.35) | 21.2 (17.70–25.14) | 2.0 (1.15–3.44) |
| Uninsured, non-Hispanic white | 71.4 (65.88–76.42) | 25.9 (21.08–31.31) | 2.7 (1.39–5.16) |
| Uninsured, non-Hispanic black/African American | 83.3 (75.61–88.95) | 15.3 (9.99–22.81) |
—
|
| Uninsured, Hispanic | 88.6 (82.71–92.67) | 10.3 (6.42–16.22) |
—
|
|
| |||
| Public, total | 37.4 (34.17–40.77) | 46.0 (42.47–49.49) | 16.6 (14.13–19.46) |
| Public, non-Hispanic white | 37.2 (33.15–41.39) | 45.2 (40.88–49.58) | 17.6 (14.49–21.27) |
| Public, non-Hispanic black/African American | 29.0 (22.49–36.48) | 55.0 (47.30–62.41) | 16.0 (11.10–22.64) |
| Public, Hispanic | 45.9 (37.71–54.35) | 42.0 (33.84–50.66) | 12.1 (8.10–17.59) |
| Private, total | 36.6 (33.38–39.91) | 45.5 (42.01–48.94) | 18.0 (15.52–20.70) |
| Private, non-Hispanic white | 36.2 (32.81–39.84) | 46.3 (42.64–50.08) | 17.4 (14.85–20.32) |
| Private, non-Hispanic black/African American | 36.7 (25.22–49.85) | 39.5 (28.98–51.01) | 23.9 (14.56–36.58) |
| Private, Hispanic | 46.0 (29.89–62.96) | 36.0 (22.03–52.77) | 18.0 (7.46–37.54) |
| Other, total | 56.3 (35.11–75.44) | 28.2 (13.89–48.78) | 15.5 (6.19–33.88) |
| Other, non-Hispanic white | 68.0 (40.81–86.71) | 21.5 (7.49–48.01) |
—
|
| Other, non-Hispanic black/African American |
—
|
—
| 37.0 (12.28–71.11) |
| Other, Hispanic |
—
| 100.0 (n/a) |
—
|
| Uninsured, total | 67.2 (39.81–86.43) | 30.7 (11.95–59.19) |
—
|
| Uninsured, non-Hispanic white | 48.1 (12.83–85.36) | 51.9 (14.64–87.17) |
—
|
| Uninsured, non-Hispanic black/African American |
—
|
—
|
—
|
| Uninsured, Hispanic | 82.8 (46.37–96.38) |
—
|
—
|
|
| |||
|
| |||
| Public, total | 84.5 (81.46–87.06) | 12.9 (10.52–15.77) | 2.6 (1.67–4.08) |
| Public, non-Hispanic white | 79.4 (74.20–83.83) | 17.2 (13.16–22.27) | 3.3 (1.74–6.27) |
| Public, non-Hispanic black/African American | 84.7 (79.63–88.76) | 11.9 (8.32–16.65) | 3.4 (1.77–6.36) |
| Public, Hispanic | 92.5 (87.48–95.56) | 7.0 (3.99–12.00) |
—
|
| Private, total | 92.5 (91.42–93.51) | 7.0 (6.05–8.12) | 0.4 (0.25–0.80) |
| Private, non-Hispanic white | 92.9 (91.56–94.06) | 6.7 (5.60–8.04) | 0.4 (0.17–0.85) |
| Private, non-Hispanic black/African American | 89.3 (85.52–92.12) | 10.0 (7.23–13.71) |
—
|
| Private, Hispanic | 91.9 (88.95–94.09) | 8.0 (5.78–10.91) |
—
|
| Other, total | 90.3 (85.59–93.57) | 8.9 (5.76–13.39) |
—
|
| Other, non-Hispanic white | 89.9 (81.99–94.51) | 8.8 (4.56–16.30) |
—
|
| Other, non-Hispanic black/African American | 89.2 (72.85–96.24) |
—
|
—
|
| Other, Hispanic | 91.8 (85.22–95.58) | 7.6 (3.97–14.20) |
—
|
| Uninsured, total | 91.7 (90.00–93.18) | 7.6 (6.16–9.32) | 0.7 (0.32–1.47) |
| Uninsured, non-Hispanic white | 90.9 (87.74–93.31) | 8.6 (6.27–11.82) |
—
|
| Uninsured, non-Hispanic black/African American | 89.7 (85.53–92.76) | 9.4 (6.48–13.36) |
—
|
| Uninsured, Hispanic | 94.2 (91.72–95.97) | 5.3 (3.59–7.76) | 0.5 (0.19–1.30) |
|
| |||
| Public, total | 33.0 (28.80–37.58) | 42.4 (38.17–46.73) | 24.6 (20.90–28.64) |
| Public, non-Hispanic white | 33.5 (27.06–40.60) | 40.7 (34.32–47.34) | 25.8 (20.77–31.65) |
| Public, non-Hispanic black/African American | 24.5 (18.52–31.71) | 53.1 (45.20–60.79) | 22.4 (16.29–30.00) |
| Public, Hispanic | 42.9 (32.46–53.93) | 33.1 (24.09–43.55) | 24.0 (16.04–34.40) |
| Private, total | 68.9 (67.00–70.69) | 26.7 (24.96–28.56) | 4.4 (3.71–5.21) |
| Private, non-Hispanic white | 70.0 (67.80–72.04) | 26.1 (24.12–28.27) | 3.9 (3.16–4.81) |
| Private, non-Hispanic black/African American | 56.7 (51.08–62.23) | 35.1 (30.22–40.42) | 8.1 (5.63–11.55) |
| Private, Hispanic | 68.9 (63.13–74.12) | 25.5 (20.87–30.67) | 5.6 (3.71–8.51) |
| Other, total | 61.4 (53.20–68.95) | 29.2 (22.62–36.83) | 9.4 (5.63–15.31) |
| Other, non-Hispanic white | 64.1 (53.02–73.78) | 28.1 (19.43–38.80) | 7.8 (3.47–16.73) |
| Other, non-Hispanic black/African American | 58.9 (41.83–74.06) | 29.1 (16.85–45.49) | 12.0 (5.18–25.27) |
| Other, Hispanic | 56.5 (37.64–73.71) | 32.9 (18.07–52.24) |
—
|
| Uninsured, total | 69.2 (65.15–73.06) | 25.2 (21.66–29.17) | 5.5 (3.84–7.89) |
| Uninsured, non-Hispanic white | 67.1 (61.45–72.28) | 26.4 (21.65–31.86) | 6.5 (4.06–10.16) |
| Uninsured, non-Hispanic black/African American | 68.8 (60.52–76.06) | 24.1 (17.56–32.22) | 7.0 (3.39–14.06) |
| Uninsured, Hispanic | 72.4 (64.16–79.31) | 25.1 (18.53–33.05) | 2.5 (0.96–6.50) |
|
| |||
| Public, total | 36.9 (34.07–39.74) | 47.2 (44.26–50.18) | 15.9 (13.87–18.23) |
| Public, non-Hispanic white | 37.4 (33.88–41.09) | 46.0 (42.27–49.82) | 16.6 (13.92–19.58) |
| Public, non-Hispanic black/African American | 32.8 (26.91–39.19) | 53.3 (46.84–59.66) | 13.9 (10.58–18.14) |
| Public, Hispanic | 36.9 (30.22–44.09) | 48.4 (41.54–55.39) | 14.7 (10.53–20.08) |
| Private, total | 38.8 (36.01–41.65) | 47.9 (45.15–50.72) | 13.3 (11.52–15.27) |
| Private, non-Hispanic white | 38.6 (35.57–41.76) | 48.3 (45.25–51.38) | 13.1 (11.19–15.21) |
| Private, non-Hispanic black/African American | 33.6 (26.28–41.86) | 52.5 (44.34–60.49) | 13.9 (8.75–21.36) |
| Private, Hispanic | 45.2 (31.56–59.62) | 34.9 (23.78–48.00) | 19.9 (10.35–34.76) |
| Other, total |
—
| 73.2 (37.60–92.52) |
—
|
| Other, non-Hispanic white |
—
| 100.0 (n/a) |
—
|
| Other, non-Hispanic black/African American |
—
|
—
|
—
|
| Other, Hispanic |
—
| 100.0 (n/a) |
—
|
| Uninsured, total | 69.4 (47.49–85.00) | 17.4 (6.66–38.32) |
—
|
| Uninsured, non-Hispanic white |
—
| 51.1 (15.43–85.71) |
—
|
| Uninsured, non-Hispanic black/African American | 60.3 (19.46–90.50) |
—
|
—
|
| Uninsured, Hispanic | 82.8 (48.96–96.04) |
—
|
—
|
Abbreviations: CI, confidence interval; n/a, not applicable.
Relative standard error (RSE) >30% and ≤50% and should be used with caution as they do not meet National Center for Health Statistics standards of reliability and precision.
RSE >50% are not shown.
Estimates with a quantity of zero.
Analysis of differences in racial/ethnic groups revealed additional patterns in the prevalence of MCC by health insurance coverage. Non-Hispanic white men aged 45 to 64 years who had public coverage had a higher prevalence of 2 to 3 MCC than those who had private coverage (
Among non-Hispanic white women aged 45 to 64 years, those with public coverage had a higher prevalence of 2 to 3 MCC (
To meet an additional objective of the HHS MCC framework — determination of the most common MCC dyads and triads (
| Sex, Age, and Dyad | % (95% Confidence Interval) |
|---|---|
|
| |
|
| |
| Arthritis/hypertension | 26.9 (22.01–32.43) |
| Diabetes/hypertension | 21.1 (16.40–26.66) |
| Asthma/hypertension | 18.6 (14.21–23.91) |
| COPD/hypertension | 13.1 (9.12–18.36) |
| Arthritis/diabetes | 9.2 (6.24–13.46) |
|
| |
| Arthritis/hypertension | 46.9 (43.71–50.17) |
| Diabetes/hypertension | 29.7 (27.02–32.50) |
| CHD/hypertension | 16.4 (14.27–18.71) |
| Arthritis/diabetes | 14.7 (12.70–17.05) |
| Cancer/hypertension | 11.3 (9.50–13.43) |
|
| |
| Arthritis/hypertension | 49.3 (46.29–52.32) |
| Diabetes/hypertension | 29.5 (26.81–32.42) |
| Cancer/hypertension | 27.6 (24.91–30.40) |
| CHD/hypertension | 24.8 (22.05–27.84) |
| Arthritis/diabetes | 21.2 (18.75–23.83) |
|
| |
|
| |
| Arthritis/hypertension | 24.6 (20.71–29.05) |
| Arthritis/asthma | 20.5 (16.84–24.80) |
| Asthma/hypertension | 19.5 (15.94–23.64) |
| Arthritis/COPD | 16.7 (13.31–20.85) |
| Diabetes/hypertension | 14.1 (11.12–17.74) |
|
| |
| Arthritis/hypertension | 49.9 (47.24–52.55) |
| Diabetes/hypertension | 23.6 (21.50–25.87) |
| Arthritis/diabetes | 17.3 (15.38–19.37) |
| Asthma/hypertension | 16.7 (14.72–18.89) |
| Arthritis/asthma | 16.6 (14.79–18.63) |
|
| |
| Arthritis/hypertension | 63.0 (60.46–65.51) |
| Diabetes/hypertension | 25.4 (23.27–27.71) |
| Arthritis/diabetes | 20.4 (18.39–22.50) |
| Cancer/hypertension | 21.8 (19.78–24.02) |
| Arthritis/cancer | 21.0 (19.05–23.07) |
Abbreviations: COPD, chronic obstructive pulmonary disease; CHD, coronary heart disease.
Within dyads, chronic conditions are listed in alphabetical order. Arthritis includes arthritis, rheumatoid arthritis, gout, lupus, and fibromyalgia.
Among US adults with at least 2 chronic conditions, the MCC dyad of ever having had arthritis and ever having had diabetes appeared across each of the various sex and age groups as 1 of the 5 most prevalent MCC dyads, with the exception of women aged 18 to 44 years (
As for the most prevalent MCC triads among US adults who had at least 3 chronic conditions (
| Sex, Age, and Triad | % (95 Confidence Interval) |
|---|---|
|
| |
|
| |
| Arthritis/diabetes/hypertension | 26.1 (16.70–38.45) |
| Asthma/diabetes/hypertension | 15.5 (7.73–28.73) |
| Arthritis/asthma/hypertension | 14.6 (7.17–27.31) |
| Arthritis/COPD/hypertension | 12.2 (6.47–21.79) |
| Arthritis/CHD/hypertension | 7.3 (3.23–15.83) |
|
| |
| Arthritis/diabetes/hypertension | 28.3 (24.34–32.66) |
| Arthritis/CHD/hypertension | 17.9 (14.52–21.86) |
| CHD/diabetes/hypertension | 14.5 (11.37–18.22) |
| Arthritis/cancer/hypertension | 11.2 (8.61–14.53) |
| Arthritis/asthma/hypertension | 10.6 (8.03–13.91) |
|
| |
| Arthritis/diabetes/hypertension | 28.2 (24.67–32.06) |
| Arthritis/cancer/hypertension | 27.5 (23.97–31.31) |
| Arthritis/CHD/hypertension | 27.2 (23.43–31.26) |
| CHD/diabetes/hypertension | 17.8 (14.66–21.48) |
| Cancer/CHD/hypertension | 14.6 (11.82–18.01) |
|
| |
|
| |
| Arthritis/asthma/COPD | 24.7 (17.68–33.50) |
| Arthritis/asthma/hypertension | 21.3 (15.09–29.09) |
| Asthma/COPD/hypertension | 19.8 (13.64–27.89) |
| Arthritis/COPD/hypertension | 19.7 (13.82–27.32) |
| Arthritis/diabetes/hypertension | 14.4 (9.65–21.03) |
|
| |
| Arthritis/diabetes/hypertension | 30.5 (27.24–34.02) |
| Arthritis/asthma/hypertension | 22.0 (19.00–25.35) |
| Arthritis/COPD/hypertension | 18.4 (15.59–21.52) |
| Arthritis/cancer/hypertension | 16.7 (13.80–20.09) |
| Arthritis/asthma/COPD | 14.4 (12.08–17.16) |
|
| |
| Arthritis/diabetes/hypertension | 32.6 (29.36–35.95) |
| Arthritis/cancer/hypertension | 26.9 (23.95–30.13) |
| Arthritis/CHD/hypertension | 19.3 (16.44–22.41) |
| Arthritis/COPD/hypertension | 16.8 (14.19–19.84) |
| Arthritis/asthma/hypertension | 16.5 (13.95–19.38) |
Abbreviations: COPD, chronic obstructive pulmonary disease; CHD, coronary heart disease.
Within triads, chronic conditions are listed in alphabetical order. Arthritis includes arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia.
Relative standard error (RSE) >30% and ≤50% and should be used with caution as they do not meet National Center for Health Statistics standards of reliability and precision.
Another common MCC triad was ever having had arthritis, currently having asthma, and ever having had hypertension, which was 1 of the 5 most prevalent triads for each sex and age group with the exception of men aged 65 years or older (
From 2001 through 2010, there was a slight (albeit significant) increasing trend among US adults for the prevalence of 2 to 3 MCC (
Prevalence of multiple chronic conditions among the total US adult population and separately, among US men and women, National Health Interview Survey for 2001 through 2010.
Sex, No. of Conditions 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Total, 2 or 3 18.1 17.8 18.2 18.7 19.0 19.1 18.5 19.9 20.6 21.1 Men, 2 or 3 15.7 15.9 16.0 16.8 17.3 17.3 17.1 17.7 19.4 19.9 Women, 2 or 3 20.4 19.6 20.3 20.3 20.6 20.6 19.7 22.0 21.8 22.3 Total, 4 or more 3.7 3.6 3.4 3.8 4.0 4.2 4.1 4.7 5.0 4.9 Men, 4 or more 3.4 3.4 3.1 3.5 3.2 3.9 3.6 4.0 4.6 4.4 Women, 4 or more 3.9 3.7 3.8 4.1 4.6 4.5 4.5 5.3 5.3 5.4
Examination of the 2001–2010 NHIS data for MCC by age showed no significant increase in the prevalence of 2 to 3 MCC or 4 or more MCC for adults aged 18 to 44 years (
Prevalence of multiple chronic conditions among US adults aged 18 to 44 years, 45 to 64 years, and 65 years or older, National Health Interview Survey for 2001 through 2010.
Age (y), No. of Conditions 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 18–44, 2 or 3 6.8 6.2 6.5 6.5 6.4 6.6 5.8 6.6 7.2 7.2 45–64, 2 or 3 24.1 24.1 24.0 24.5 25.2 24.8 24.6 26.2 27.2 28.1 ≥65, 2 or 3 44.2 43.4 44.5 45.6 46.0 45.7 44.6 46.1 46.3 46.5 18–44, 4 or more 0.6 0.5 0.3 0.5 0.6 0.5 0.5 0.6 0.7 0.6 45–64, 4 or more 4.6 4.4 4.4 4.5 4.6 5.3 5.0 5.3 5.6 5.7 ≥65, 4 or more 12.0 12.0 11.5 13.1 13.3 13.2 13.0 15.2 16.1 15.6
For the prevalence of MCC from 2001 through 2010 by race/ethnicity (
Prevalence of multiple chronic conditions among non-Hispanic white, non-Hispanic black, and Hispanic adults in the United States, National Health Interview Survey for 2001 through 2010.
Race, No. of Conditions 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Non-Hispanic white, 2 or 3 19.4 19.2 19.9 20.2 20.6 21.0 20.1 21.6 22.5 22.7 Non-Hispanic black/African American, 2 or 3 19.2 18.6 18.7 19.2 20.3 19.2 19.3 20.7 21.7 23.1 Hispanic, 2 or 3 11.7 10.9 10.4 10.9 11.4 11.3 11.6 12.3 13.3 14.2 Non-Hispanic white, 4 or more 3.9 3.8 3.7 4.2 4.3 4.6 4.4 5.3 5.5 5.4 Non-Hispanic black/African American, 4 or more 3.9 3.8 4.2 3.8 4.0 5.1 4.7 4.4 5.4 5.4 Hispanic, 4 or more 2.3 2.0 1.5 2.5 2.3 1.7 2.2 2.4 2.7 2.7
The main objective of our study was to use the NHIS to examine the prevalence of MCC by select sociodemographic groups and the prevalence of MCC dyads and triads. The results showed that more than one-quarter of US adults have MCC. Among certain subgroups (such as women and older adults), the prevalence of MCC was generally higher, and for others (Hispanic adults and those with private insurance) the prevalence was generally lower. Not surprisingly (
Although MCC prevalences presented in this study are generalizable to the US adult noninstitutionalized civilian population, use of the NHIS has limitations. Only 10 conditions detailed in the HHS Interagency Workgroup definition (
In spite of these limitations, examining the prevalence of MCC among subgroups of adults allows for the identification of MCC patterns in the US adult population. Our research serves as a platform from which additional research using the NHIS can build. It would be beneficial for future studies to seek to explain why differences in the prevalence of MCC among subgroups exist. This might entail examining topics such as how different health insurance types influence service use and the likelihood of being diagnosed with a chronic condition, how educational attainment may affect MCC, or what behavioral risk factors are most common among adults with MCC.
Our study shows that the increasing trend in the prevalence of MCC among US adults is a cause for concern, and the NHIS can be a useful data source for identifying patterns of MCC at the national level and assessing which population subgroups are most likely to have MCC. This information can be useful in helping clinicians develop prevention strategies tailored to population subgroups with greater prevalence of MCC and subgroups that are most at risk for complications resulting from specific dyads and triads, consequently reducing health care costs among these subgroups.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.